| Original language | English (US) |
|---|---|
| Article number | 1901866 |
| Journal | European Respiratory Journal |
| Volume | 55 |
| Issue number | 1 |
| DOIs | |
| State | Published - Jan 1 2020 |
ASJC Scopus subject areas
- Pulmonary and Respiratory Medicine
Access to Document
Other files and links
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
In: European Respiratory Journal, Vol. 55, No. 1, 1901866, 01.01.2020.
Research output: Contribution to journal › Letter › peer-review
}
TY - JOUR
T1 - Connected real-life research, a pillar of P4 medicine
AU - Roche, Nicolas
AU - Anzueto, Antonio
AU - Anticevich, Sinthia Bosnic
AU - Kaplan, Alan
AU - Miravitlles, Marc
AU - Ryan, Dermot
AU - Soriano, Joan B.
AU - Usmani, Omar
AU - Papadopoulos, Nikos
AU - Walter Canonica, G.
N1 - Funding Information: Conflict of interest: N. Roche reports grants and personal fees from Boehringer Ingelheim, Novartis and Pfizer, personal fees from Teva, GSK, AstraZeneca, Chiesi, Mundipharma, Sanofi, Sandoz, 3M, Zambon and Trudell, outside the submitted work. A. Anzueto reports personal fees for consultancy from GlaxoSmithKline, AstraZeneca and Boehringer Ingelheim, outside the submitted work. S. Bosnic Anticevich reports personal fees for advisory board work from TEVA, personal fees for consultancy from GSK and MEDA, grants from TEVA, personal fees for lectures from TEVA, GSK and AstraZeneca, personal fees for manuscript preparation from MEDA, personal fees for educational activities from GSK, outside the submitted work. A. Kaplan reports grants and personal fees from AstraZeneca, Boehringer Ingelheim and Pfizer, personal fees from Covis, GSK, Sanofi, Merck Frosst, Novartis, Purdue, Teva, Trudel, Novo Nordisk and Griffols, during the conduct of the study. M. Miravitlles reports personal fees for lectures from AstraZeneca, Boehringer Ingelheim, Chiesi, Cipla, Menarini, Rovi, Bial, Zambon, CSL Behring, Grifols and Novartis, personal fees for consultancy from AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Bial, Gebro Pharma, CSL Behring, Laboratorios Esteve, Ferrer, Mereo Biopharma, Verona Pharma, TEVA, pH Pharma, Novartis and Grifols, grants from GlaxoSmithKline and Grifols, outside the submitted work. D. Ryan reports personal fees for advisory board work from GSK, BI, AZ and Novartis, personal fees for lectures from AZ and MEDA, grants meeting registration from MEDA, outside the submitted work; and is Previous President and Current Vice President of REG, and Consultant Strategic Medical Adviser, Optimum Patient Care. J.B. Soriano participated in speaking activities, advisory committees and consultancies during the period 2014–2019 sponsored by: Almirall, AstraZeneca, Boehringer Ingelheim, CHEST, Chiesi, ERS, GEBRO, Grifols, GSK, Linde, Lipopharma, Mundipharma, Novartis, Pfizer, RiRL, Rovi, Sandoz, SEPAR and Takeda; J.B. Soriano declares not receiving ever, directly or indirectly, funding from the tobacco industry or its affiliates. O. Usmani reports grants and personal fees from AstraZeneca, Boehringer Ingelheim and Chiesi, personal fees from Aerocrine, Napp, Mundipharma, Sandoz, Takeda, Zentiva and Cipla, grants from GlaxoSmithKline and Edmond Pharma, outside the submitted work. N. Papadopoulos reports personal fees for advisory board work and lectures from Novartis, Nutricia, HAL, MENARINI/FAES FARMA and MYLAN/MEDA, personal fees for lectures from SANOFI, BIOMAY, MSD, ASIT BIOTECH and Boehringer Ingelheim, personal fees for advisory board work from AstraZeneca and GSK, grants from Gerolymatos International SA and Capricare, outside the submitted work. G.W. Canonica has nothing to disclose.
PY - 2020/1/1
Y1 - 2020/1/1
UR - https://www.scopus.com/pages/publications/85077940941
UR - https://www.scopus.com/pages/publications/85077940941#tab=citedBy
U2 - 10.1183/13993003.02287-2019
DO - 10.1183/13993003.02287-2019
M3 - Letter
C2 - 31949104
AN - SCOPUS:85077940941
SN - 0903-1936
VL - 55
JO - European Respiratory Journal
JF - European Respiratory Journal
IS - 1
M1 - 1901866
ER -